2024-05-20
The National Medical Products Administration approved the launch of the combination package of sulbactam sodium injection/dulobactam sodium injection
Recently, the National Medical Products Administration (NMPA) approved the marketing of Entasis Therapeutics, Inc.'s innovative Category 1 sulbactam sodium injection/dulobactam sodium injection combination package (trade name: XACDURO) through priority review and approval. This drug is indicated for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible isolates of the Acinetobacter baumannii-calcoaceticus complex in patients aged 18 years and older.
This product is a combination package containing sulbactam sodium for injection and dulobactam sodium for injection. Sulbactam is a β-lactam antibacterial drug and an Ambler A class serine β-lactamase inhibitor. Dulobactam is a diazabicyclooctane, non-β-lactam β-lactamase inhibitor that protects sulbactam from degradation by β-lactamases. This product, now available, provides a new treatment option for patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible isolates of the Acinetobacter baumannii-calcoaceticus complex.
This product is a combination package containing sulbactam sodium for injection and dulobactam sodium for injection. Sulbactam is a β-lactam antibacterial drug and an Ambler A class serine β-lactamase inhibitor. Dulobactam is a diazabicyclooctane, non-β-lactam β-lactamase inhibitor that protects sulbactam from degradation by β-lactamases. This product, now available, provides a new treatment option for patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible isolates of the Acinetobacter baumannii-calcoaceticus complex.
